Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two ...
Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...
Also Read: Sanofi’s Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant. Preliminary analysis of liver safety was consistent with ...
Good morning! Today, we discuss the woman who spearheaded progress in multiple myeloma for decades, see mixed but promising results from Sanofi’s multiple sclerosis drug, and hear why All of Us ...
London: Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in ...
The potential of Sanofi’s closely-watched BTK inhibitor in multiple sclerosis is coming into clearer view amid plans to narrow the focus of the French company’ … ...
Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease ...
But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...
By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive ...
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...
Sanofi's Mixed Fortunes in MS Drug Trials Has Market Focus on Win By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage ...
At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback